MedTrace Logo

Study on the Mass Balance of [14C] CMS-D002 in Healthy Adult Participants in China

NCT07788482 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 10

Last updated 2026-08-26

No results posted yet for this study

Summary

This phase 1, single-group study will evaluate the mass balance of \[14C\] CMS-D002 after a single oral dose in healthy adult participants in China. The study will assess total radioactivity recovery and routes of excretion, characterize whole-blood and plasma pharmacokinetics, and determine metabolite profiles and major biotransformation pathways.

Conditions

  • Healthy Volunteers

Interventions

DRUG

[14C] CMS-D002

Single oral dose administration of \[14C\] CMS-D002.

Sponsors & Collaborators

  • Shenzhen Kangzhe Biotechnology Co., Ltd.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
BASIC_SCIENCE
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-09-30
Primary Completion
2026-12-31
Completion
2027-04-30

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07788482 on ClinicalTrials.gov